- Home
- HEPS vs VTYX Comparison
HEPS vs VTYX Comparison
Compare HEPS & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HEPS | VTYX |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.4M | 990.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HEPS | VTYX |
|---|---|---|
| Price | $2.82 | $13.98 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 7 |
| Target Price | $3.07 | ★ $13.50 |
| AVG Volume (30 Days) | 229.0K | ★ 5.9M |
| Earning Date | 11-05-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,504,533,586.00 | N/A |
| Revenue This Year | $41.69 | N/A |
| Revenue Next Year | $29.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 56.77 | N/A |
| 52 Week Low | $2.15 | $0.78 |
| 52 Week High | $3.85 | $25.00 |
Technical Indicators
Market Signals| Indicator | HEPS | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 61.68 | 75.73 |
| Support Level | $2.72 | $7.08 |
| Resistance Level | $2.85 | $14.07 |
| Average True Range (ATR) | 0.10 | 0.27 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 82.46 | 83.47 |
Price Performance
Historical ComparisonAbout HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.